Embecta Corp. — Form 8-K/A
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 28/100
What the filing says
On May 15, 2026, Embecta Corp. completed acquisition of Owen Mumford Holdings Limited (UK-based medical device manufacturer) for £100M (~$166.1M) cash at closing plus £26M (~$34.3M) net cash, plus contingent earn-out up to £50M (~$65.9M) tied to Aidaptus® auto-injector net sales over three years post-closing. Owen Mumford's FY2025 revenue was £68.6M (~$92.1M); net income £1.7M (~$2.3M). The acquisition was financed via $180M draw on Embecta's revolving credit facility. Pro forma combined FY2025 revenue ~$1.17B; pro forma combined H1 FY2026 revenue $526.5M.
Why this rating
Acquisition is ~23% of Embecta's market cap ($732M), meaningful but moderate. Owen Mumford is profitable but modest scale. Funded via existing revolver; no equity dilution disclosed. Strategic bolt-on, not transformational for large acquirer.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.